AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2217
-0.0052 (-2.29%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AIM ImmunoTech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.1 | 0.09 | 0.17 | 0.2 | 0.14 | 0.14 | |
Revenue Growth | -21.49% | -48.23% | -15.84% | 43.26% | 4.44% | -17.18% |
Cost of Revenue | 0.12 | 0.13 | 0.03 | 0.04 | - | 0.85 |
Gross Profit | -0.02 | -0.04 | 0.14 | 0.16 | 0.14 | -0.72 |
Selling, General & Admin | 8.71 | 8.07 | 14.16 | 21.64 | 13.29 | 8.67 |
Research & Development | 2.41 | 3.55 | 5.75 | 10.44 | 6.77 | 7.67 |
Operating Expenses | 11.12 | 11.62 | 19.91 | 32.08 | 20.06 | 16.34 |
Operating Income | -11.14 | -11.66 | -19.77 | -31.92 | -19.92 | -17.06 |
Interest Expense | -1.17 | -0.81 | -0.59 | - | - | -0.07 |
Interest & Investment Income | 0.15 | 0.14 | 0.29 | 1.07 | 0.63 | - |
Other Non Operating Income (Expenses) | -5.15 | -4.68 | 2.85 | 1.67 | 1.53 | 2.46 |
EBT Excluding Unusual Items | -17.31 | -17.02 | -17.23 | -29.18 | -17.77 | -14.66 |
Gain (Loss) on Sale of Investments | -0 | 0.02 | -0.09 | 0.2 | -1.68 | -0.2 |
Gain (Loss) on Sale of Assets | - | - | - | 0.02 | 0 | 0.22 |
Asset Writedown | - | - | - | - | - | -1.78 |
Other Unusual Items | 3.04 | 3.04 | - | - | - | -2.7 |
Pretax Income | -14.27 | -13.96 | -17.32 | -28.96 | -19.45 | -19.13 |
Net Income | -14.27 | -13.96 | -17.32 | -28.96 | -19.45 | -19.13 |
Net Income to Common | -14.27 | -13.96 | -17.32 | -28.96 | -19.45 | -19.13 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 7 | 2 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 7 | 2 | 1 | 0 | 0 | 0 |
Shares Change | 894.51% | 188.95% | 15.18% | 1.12% | 1.49% | 48.67% |
EPS (Basic) | -2.14 | -8.62 | -30.92 | -59.55 | -40.43 | -40.36 |
EPS (Diluted) | -2.14 | -8.62 | -30.92 | -59.55 | -40.43 | -40.36 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -14.37 | -10.96 | -14.91 | -21.27 | -16.19 | -14.01 |
Free Cash Flow Per Share | -2.16 | -6.77 | -26.61 | -43.73 | -33.67 | -29.56 |
Gross Margin | -23.16% | -45.45% | 81.77% | 79.21% | 100.00% | - |
Operating Margin | -11724.21% | -13254.54% | -11630.59% | -15800.00% | -14129.79% | -12636.30% |
Profit Margin | -15021.05% | -15861.36% | -10188.24% | -14337.62% | -13790.78% | -14168.15% |
Free Cash Flow Margin | -15130.53% | -12451.14% | -8768.24% | -10528.22% | -11485.11% | -10374.81% |
EBITDA | -10.73 | -11.45 | -19.53 | -31.68 | -19.67 | -16.28 |
D&A For EBITDA | 0.4 | 0.21 | 0.25 | 0.24 | 0.26 | 0.78 |
EBIT | -11.14 | -11.66 | -19.77 | -31.92 | -19.92 | -17.06 |
Revenue as Reported | 0.1 | 0.09 | 0.17 | 0.2 | 0.14 | 0.14 |